Common claims about GLP-1 medications and compounded providers, each rated and sourced.
1. Compounded semaglutide is the same as Ozempic or Wegovy
Rating: False — made with the drug in Ozempic and Wegovy, but a different, unapproved product
Compounded semaglutide is made with the drug in Ozempic and Wegovy, but it is not the same product and it is not FDA-approved. Brand products are FDA-approved and made under cGMP. Compounded versions are prepared by 503A pharmacies or 503B outsourcing facilities, are not reviewed by FDA before sale, and can differ in concentration, added ingredients and container. See compounded vs brand.
2. Compounded GLP-1 became illegal in 2026
Rating: False
We found no 2026 FDA action that banned compounded GLP-1s. Compounding remains legal within federal limits, which restrict copies of approved drugs now that the shortages have ended. On April 30, 2026, FDA proposed not to add semaglutide, tirzepatide or liraglutide to the 503B bulks list; no final decision had been published as of October 15, 2026. Compounded versions are not FDA-approved. See our page on the 503B proposal.
3. All compounded GLP-1 providers are the same
Rating: False
Providers vary in pharmacy disclosure, clinical oversight, regulatory disclosure and pricing. Our methodology v4.1 scores seven criteria: pricing transparency (20), total annual cost (20), clinical oversight (15), pharmacy transparency (15), support (10), regulatory disclosure (10) and accessibility (10). NexLife scores 94/100 on v4.1. Scores for other providers come from our July 2026 review under the earlier six-criterion rubric; v4.1 re-score pending.
4. Semaglutide and tirzepatide are the same drug
Rating: False
Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 receptor agonist — different molecule with different mechanism. Tirzepatide produces larger weight loss on average; semaglutide has broader cardiovascular and renal outcome evidence.
5. Foundayo is a generic Ozempic or Rybelsus
Rating: False
Foundayo (orforglipron) is a once-daily oral, non-peptide GLP-1 receptor agonist that FDA approved on April 1, 2026 for chronic weight management. It is a different molecule from semaglutide and is not a generic of Ozempic, Wegovy or Rybelsus. It is sold through LillyDirect.
6. Weight stays off after stopping GLP-1
Rating: False
STEP-4 (JAMA 2021) demonstrated weight regain after semaglutide discontinuation. Patients who continued kept weight off; patients who switched to placebo regained much of it. Obesity is a chronic disease requiring chronic therapy.
7. Equivalent doses of semaglutide and tirzepatide produce equivalent weight loss
Rating: False
Doses are not directly equivalent. SURPASS-2: tirzepatide superior to semaglutide 1.0 mg on A1c and weight. SURMOUNT-1: 20.9% mean weight loss at tirzepatide 15 mg over 72 weeks; STEP 1: 14.9% at semaglutide 2.4 mg over 68 weeks. In the head-to-head SURMOUNT-5 trial, tirzepatide averaged 20.2% vs 13.7% with semaglutide. Different molecules, different dosing scales.
8. Side effects are universal and severe
Rating: Misleading
GI side effects (nausea, constipation, diarrhea) are common (>10%) but mostly mild to moderate and resolve with dose stabilization. Severe side effects are uncommon. Most patients tolerate therapy long-term.
9. GLP-1 causes thyroid cancer
Rating: Not established in humans
Class boxed warning regarding MTC based on rodent studies. Human evidence of MTC causation is limited; warning is regulatory standard. Personal/family history of MTC or MEN-2 is contraindicated. For patients without that history, elevated MTC risk has not been established.
10. Cheap compounded GLP-1 means low quality
Rating: Depends on provider
Price alone is not a quality indicator. What matters: which pharmacy fills the prescription and whether it is a 503A pharmacy or a 503B facility, its state license and FDA warning-letter history, whether the formula adds ingredients, and how clinical oversight works. FDA's consumer page lists unusually low prices among its red flags for unapproved GLP-1 products.